In cervical cancer, glioma, and other tumors, FGFR3-TACC3 is a recurrent and carcinogenic fusion [46, 79], and is sensitive to FGFR inhibitors [83]; therefore, FGFR3-TACC3 fusion protein inhibitors have the potential to treat fusion-positive cancers. This evidence concerns the gene FGFR3 and cervical cancer.